Relay Therapeutics to advance Zovegalisib to Phase 3 breast cancer trial
Relay Therapeutics (NASDAQ:RLAY) announced on Monday that it will advance its lead candidate, zovegalisib, into a planned Phase 3 frontline trial for the treatment of PIK3CA-mutated, HR+/HER2- metastatic breast cancer.



-640x360.webp&w=3840&q=75)

_1387413_640x360_2497849411974-640x360.webp&w=3840&q=75)





